Brigatinib – Uses, Dosage, Side Effects, Interaction Brigatinib is an orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Brigatinib binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible tumor cells. In addition, AP26113 appears to overcome mutation-based resistance. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. EGFR is overexpressed in a variety of cancer cell types. Brigatinib is a tyrosine kinase receptor inhibitor and antineoplastic agent used in the therapy of selected forms of advanced non-small cell lung cancer. Brigatinib is associated with a moderate rate of transient elevations in serum aminotransferase levels during therapy but has yet to be linked to instances of clinically apparent acute liver injury. Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and was FDA-approved on April 28, 2017. Mechanism of Action Brigitanib acts as a tyrosine kinase inhibitor with activity against multiple kinases including ALK, ROS1, insulin-like growth factor 1 receptor, and EGFR deletions and point mutations. It acts by inhibiting ALK phosphorylation and the activation of downstream signaling proteins. Brigitanib inhibits the proliferation and in vitro viability of cells expressing the fusion protein EML4-ALK as well as 17 crizotinib-resistant ALK mutants. Its action is expanded to cells expressing EGFR deletions, ROS1-L2026M, FLT3-F691L, and FLT3-D835Y. Brigitanib presents a dose-dependent inhibition of tumor growth, tumor burden, and prolonged survival in mice EML4-ALK xenograft models. The Time course of Brigatinib and exposure-response studies are still unknown. or Brigatinib is an inhibitor of ALK and mutated EGFR. ALK was first identified as a chromosomal rearrangement in anaplastic large cell lymphoma (ALCL). Genetic studies indicate that abnormal expression of ALK is a key driver of certain types of non-small cell lung cancer (NSCLC) and neuroblastomas, as well as ALCL. Since ALK is generally not expressed in normal adult tissues, it represents a highly promising molecular target for cancer therapy. Brigatinib inhibits ROS proto-oncogene-1 fusions and EGFR mutations and has a remarkable effect on the central nervous system.[rx] Epidermal growth factor receptor (EGFR) is another validated target in NSCLC. Additionally, the T790M “gatekeeper” mutation is linked in approximately 50 percent of patients who grow resistant to first-generation EGFR inhibitors.[rx] While second-generation EGFR inhibitors are in development, clinical efficacy has been limited due to toxicity thought to be associated with inhibiting the native (endogenous or unmutated) EGFR. A therapy designed to target EGFR, the T790M mutation but avoiding inhibition of native EGFR is another promising molecular target for cancer therapy. Indications The anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the ALK mutation, overexpression, and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target. The ALK-related cases of NSCLC are associated with the presence of the fusion gene EML4-ALK which fused the ALK protein with the echinoderm microtubule-associated protein like-4 whose original function is the correct formation of microtubules. The presence of the aberrant fusion protein results in abnormal signaling that provokes increased cell growth, proliferation, and survival. Crizotinib is indicated for the treatment of such cases but the presence of ALK kinase domain mutations confers resistance to the treatment. Thus, brigatinib is indicated for the treatment of patients with ALK+ NSCLC with intolerance to Crizotinib. Brigatinib is a tyrosine kinase receptor inhibitor and antineoplastic agent used in the therapy of selected forms of advanced non-small cell lung cancer Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase ALKpositive advanced NSCLC previously treated with crizotinib. Metastatic Non-Small Cell Lung Cancer Use in Cancer Brigatinib is approved to treat: Non-small cell lung cancer that is ALK-positive and has metastasized (spread to other parts of the body). It is used in adults. Brigatinib is also being studied in the treatment of other types of cancer. Contraindications high blood pressure slow heartbeat high amount of bilirubin in the blood high blood sugar abnormal liver function tests pregnancy a patient who is producing milk and breastfeeding increased creatine kinase levels lung tissue problem high blood levels of the lipase enzyme high blood levels of the amylase enzyme chronic kidney disease stage 4 (severe) kidney disease with likely reduction in kidney function Child-Pugh class C liver impairment Dosage Strengths: 90 mg; 30 mg; 180 mg; 90 mg-180 mg Non-Small Cell Lung Cancer Initial dose: 90 mg orally once a day for the first 7 days Maintenance dose: 180 mg orally once a day Patients should be selected for the treatment of metastatic NSCLC based on the presence of ALK positivity in tumor specimens. FDA-approved test for the detection of ALK rearrangements in NSCLC is available at http://www.fda.gov/CompanionDiagnostic Treatment should be continued until the disease progresses or has unacceptable toxicity. Renal Dose Adjustments Mild to moderate renal dysfunction (CrCl 30 to 89 mL/min): No adjustment is recommended. Severe renal dysfunction (CrCl 15 to 29 mL/min): Reduce once-daily dose by approximately 50% (i.e., from 180 mg to 90 mg OR 90 mg to 60 mg). Liver Dose Adjustments Mild to moderate liver dysfunction (Child-Pugh A to B): No adjustment recommended. Severe liver dysfunction (Child-Pugh C): Reduce once-daily dose by approximately 40% (i.e., from 180 mg to 120 mg, OR 120 mg to 90 mg, OR 90 mg to 60 mg). Dose Adjustments DOSE REDUCTION FOR ADVERSE REACTIONS: STARTING DOSE 90 MG ONCE A DAY: First reduction: 60 mg once a day Second reduction: Permanently discontinue therapy. Third reduction: N/A STARTING DOSE 180 MG ONCE A DAY: First reduction: 120 mg once a day Second reduction: 90 mg once a day Third reduction: 60 mg once a da Once the dose is reduced, do not subsequently increase the dose. Permanently discontinue this drug if patients are unable to tolerate 60 mg once a day. Dosing interruption of 14 days or longer (for reasons other than adverse reactions): Resume at 90 mg once a day for 7 days before increasing to the previously tolerated dose. STRONG OR MODERATE CYP450 3A INHIBITORS: Avoid concomitant use. If concomitant use of a strong CYP450 3A inhibitor cannot be avoided, reduce the once-a-day dose of this drug by approximately 50% (i.e., from 180 mg to 90 mg OR from 90 mg to 60 mg). If coadministration of a moderate CYP450 3A inhibitor cannot be avoided, reduce the once-daily dose of this drug by approximately 40% (i.e., from 180 mg to 120 mg, OR 120 mg to 90 mg, OR from 90 mg to 60 mg). After discontinuation of a strong or moderate CYP450 3A inhibitor, resume the dose of this drug that was tolerated prior to initiating the CYP450 3A inhibitor. MODERATE CYP450 3A INDUCERS: Avoid concomitant use. If coadministration of a moderate CYP450 3A inducer cannot be avoided, increase the once-daily dose of this drug in 30 mg increments after 7 days of therapy with the current dose as tolerated, up to a maximum of twice the dose that was tolerated prior to initiating the moderate CYP450 3A inducer. After discontinuation of a moderate CYP450 3A inducer, resume the dose of this drug that was tolerated prior to initiating the moderate CYP450 3A inducer. DOSE MODIFICATIONS FOR ADVERSE REACTIONS: INTERSTITIAL LUNG DISEASE (ILD)/PNEUMONITIS: GRADE 1: If new pulmonary symptoms occur during the first 7 days of therapy, withhold this drug until recovery to baseline, then resume at the same dose and do not escalate to 180 mg if ILD/pneumonitis is suspected. If new pulmonary symptoms occur after the first 7 days of therapy, withhold this drug until recovery to baseline, then resume at same dose. If ILD/pneumonitis recurs, permanently discontinue this drug. GRADE 2: If new pulmonary symptoms occur during the first 7 days of therapy, withhold this drug until recovery to baseline; resume at the next lower dose and do not dose escalate if ILD/pneumonitis is suspected. If new pulmonary symptoms occur after the first 7 days of therapy, withhold this drug until recovery to baseline. If ILD/pneumonitis is suspected, resume at the next lower dose; otherwise, resume at the same dose. If ILD/pneumonitis recurs, permanently discontinue this drug. Grade 3 or 4: Permanently discontinue this drug. HYPERTENSION: *GRADE 3 (SBP 160 mmHg or greater or DBP 100 mmHg or greater, medical intervention indicated, more than 1 antihypertensive drug, or more intensive therapy than previously used indicated): Withhold dosing until recovery to Grade 1 or less (SBP less than 140 mmHg and DBP less than 90 mmHg) then resume at the next lower dose. Recurrence: Withhold the drug until recovery to Grade 1 or less and resume at next lower dose or permanently discontinue this drug. GRADE 4 (life-threatening consequences, urgent intervention indicated): Withhold this drug until recovery to Grade 1 or less and resume at the next lower dose OR permanently discontinue this drug. GRADE 4 RECURRENCE: Permanently discontinue this drug. BRADYCARDIA (HR less than 60 bpm): *SYMPTOMATIC BRADYCARDIA: Withhold this drug until recovery to asymptomatic bradycardia or to a resting heart rate of 60 bpm or above. If a concomitant medication known to cause bradycardia is identified and discontinued or dose-adjusted, resume this drug at the same dose upon recovery to asymptomatic bradycardia or to a resting heart rate of 60 bpm or above. If no concomitant medication known to cause bradycardia is identified, or if contributing concomitant medications are not discontinued or dose-adjusted, resume this drug at next lower dose upon recovery to asymptomatic bradycardia or to resting heart rate of 60 bpm or above. LIFE-THREATENING BRADYCARDIA (urgent intervention indicated): Permanently discontinue this drug if no contributing concomitant medication is identified. If contributing concomitant medication is identified and discontinued or dose-adjusted, resume this drug at next lower dose upon recovery to asymptomatic bradycardia or to a resting heart rate of 60 bpm or above, with frequent monitoring as clinically indicated. Recurrence: Permanently discontinue this drug. VISUAL DISTURBANCE: GRADE 2 OR 3: Withhold this drug until recovery to Grade 1 or baseline, then resume at the next lower dose. GRADE 4: Permanently discontinue this drug. CREATINE PHOSPHOKINASE (CPK) ELEVATION: *GRADE 3 OR 4 CPK ELEVATION (greater than 5 times upper level of normal [ULN] with Grade 2 or higher muscle pain or weakness): Withhold this drug until recovery to Grade 1 or less ((less than or equal to 2.5 x ULN) or to baseline, then resume at the same dose. Recurrence: Withhold until recovery to Grade 1 or less (less than or equal to 2.5 x ULN) or to baseline, then resume at the next lower dose LIPASE/AMYLASE ELEVATION: GRADE 3 (greater than 2 x ULN): Withhold this drug until recovery to Grade 1 or less (1.5 x ULN or less) or to baseline, then resume at the same dose. RECURRENCE: Withhold until recovery to Grade 1 or less (less than or equal to 1.5 x ULN) or to baseline, then resume at the next lower dose. GRADE 4 (greater than 5 x ULN): Withhold dosing until recovery to Grade 1 or less (1.5 x ULN or less) or to baseline, then resume at the next lower dose. HYPERGLYCEMIA: *GRADE 3 (greater than 250 mg/dL OR 13.9 mmol/L) OR GRADE 4: Withhold this drug until adequate hyperglycemic control is achieved and resume at the next lower dose OR permanently discontinue therapy. OTHER ADVERSE REACTIONS: *GRADE 3: Withhold this drug until recovery to baseline, then resume at the same dose. Recurrence: Withhold this drug until recovery to baseline, then resume at the next lower dose OR discontinue therapy. *GRADE 4: Withhold dosing until recovery to baseline, then resume at the next lower dose. Recurrence: Permanently discontinue therapy. Side Effects The Most Common nausea diarrhea vomiting constipation tiredness rash headache numbness, pain, tingling, or burning feeling in the feet or hands back or joint pain loss of appetite difficulty falling asleep or staying asleep More Common shortness of breath or difficulty breathing chest pain cough with or without mucus fever headache, dizziness, lightheadedness, or feeling faint blurred or double vision seeing flashes of light light hurting your eyes seeing ”floaters” or small specks extreme thirst, frequent urination, extreme hunger, blurred vision, or weakness upper stomach pain that may spread to the back or get worse with eating; weight loss; or nausea slow or irregular heartbeat muscle pain, spasms, tenderness, or weakness Rare lung problems–cough, trouble breathing, chest pain, fever; vision problems–blurred vision, double vision, increased sensitivity to light, seeing flashes of light or “floaters” in your vision; high blood pressure–severe headache, pounding in your neck or ears, dizziness; high blood sugar–increased thirst, increased urination, hunger, nausea, fruity breath odor, weakness, confusion; heart problems–very slow heartbeats, feeling like you might pass out; muscle problems–unexplained muscle pain or weakness; or pancreatitis–upper stomach pain (worse with eating and may spread to your back), nausea, weight loss. Drug Interaction DRUG INTERACTION Abaloparatide The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Brigatinib. Abametapir The serum concentration of Brigatinib can be increased when it is combined with Abametapir. Abatacept The metabolism of Brigatinib can be increased when combined with Abatacept. Abemaciclib The excretion of Abemaciclib can be decreased when combined with Brigatinib. Abiraterone The metabolism of Brigatinib can be decreased when combined with Abiraterone. Acalabrutinib The metabolism of Brigatinib can be decreased when combined with Acalabrutinib. Acenocoumarol The metabolism of Acenocoumarol can be increased when combined with Brigatinib. Acetaminophen The metabolism of Brigatinib can be increased when combined with Acetaminophen. Acetazolamide The metabolism of Brigatinib can be decreased when combined with Acetazolamide. Acyclovir The excretion of Acyclovir can be decreased when combined with Brigatinib. Adalimumab The metabolism of Brigatinib can be increased when combined with Adalimumab. Afatinib Afatinib may decrease the excretion rate of Brigatinib which could result in a higher serum level. Albendazole The metabolism of Brigatinib can be decreased when combined with Albendazole. Aldesleukin The metabolism of Brigatinib can be decreased when combined with Aldesleukin. Alectinib Alectinib may decrease the excretion rate of Brigatinib which could result in a higher serum level. Allopurinol Brigatinib may decrease the excretion rate of Allopurinol which could result in a higher serum level. Almotriptan The metabolism of Brigatinib can be decreased when combined with Almotriptan. Alpelisib The serum concentration of Alpelisib can be increased when it is combined with Brigatinib. Aminoglutethimide The metabolism of Brigatinib can be increased when combined with Aminoglutethimide. Aminophenazone The metabolism of Brigatinib can be decreased when combined with Aminophenazone. Amiodarone The metabolism of Brigatinib can be decreased when combined with Amiodarone. Amitriptyline The metabolism of Brigatinib can be decreased when combined with Amitriptyline. Amobarbital The metabolism of Brigatinib can be increased when combined with Amobarbital. Amodiaquine The metabolism of Brigatinib can be decreased when combined with Amodiaquine. Amprenavir The metabolism of Brigatinib can be decreased when combined with Amprenavir. Anakinra The metabolism of Brigatinib can be increased when combined with Anakinra. Anastrozole The metabolism of Brigatinib can be decreased when combined with Anastrozole. Antipyrine The metabolism of Brigatinib can be decreased when combined with Antipyrine. Apalutamide The metabolism of Brigatinib can be increased when combined with Apalutamide. Apixaban The metabolism of Brigatinib can be decreased when combined with Apixaban. Apomorphine The metabolism of Brigatinib can be decreased when combined with Apomorphine. Apremilast The metabolism of Brigatinib can be increased when combined with Apremilast. Aprepitant The metabolism of Brigatinib can be decreased when combined with Aprepitant. Aripiprazole The metabolism of Aripiprazole can be increased when combined with Brigatinib. Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be increased when combined with Brigatinib. Armodafinil The metabolism of Brigatinib can be increased when combined with Armodafinil. Articaine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Articaine. Asciminib The serum concentration of Brigatinib can be increased when it is combined with Asciminib. Astemizole The metabolism of Brigatinib can be decreased when combined with Astemizole. Asunaprevir The metabolism of Brigatinib can be increased when combined with Asunaprevir. Atazanavir The metabolism of Brigatinib can be decreased when combined with Atazanavir. Atorvastatin The metabolism of Brigatinib can be decreased when combined with Atorvastatin. Avacopan The metabolism of Brigatinib can be decreased when combined with Avacopan. Avanafil The serum concentration of Avanafil can be increased when it is combined with Brigatinib. Avatrombopag The metabolism of Brigatinib can be increased when combined with Avatrombopag. Azelastine The metabolism of Brigatinib can be decreased when combined with Azelastine. Azithromycin The metabolism of Brigatinib can be decreased when combined with Azithromycin. Baricitinib The excretion of Baricitinib can be decreased when combined with Brigatinib. Beclomethasone The metabolism of Brigatinib can be increased when combined with Beclomethasone dipropionate. Belumosudil Belumosudil may decrease the excretion rate of Brigatinib which could result in a higher serum level. Belzutifan The serum concentration of Brigatinib can be decreased when it is combined with Belzutifan. Benzocaine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Benzyl alcohol. Berotralstat The serum concentration of Berotralstat can be increased when it is combined with Brigatinib. Betamethasone The metabolism of Brigatinib can be increased when combined with Betamethasone. Betamethasone The metabolism of Brigatinib can be increased when combined with Betamethasone phosphate. Bexarotene The metabolism of Brigatinib can be increased when combined with Bexarotene. Bezafibrate The metabolism of Brigatinib can be decreased when combined with Bezafibrate. Bicalutamide The metabolism of Brigatinib can be decreased when combined with Bicalutamide. Bifonazole The metabolism of Brigatinib can be decreased when combined with Bifonazole. Bimekizumab The metabolism of Brigatinib can be increased when combined with Bimekizumab. Boceprevir The metabolism of Brigatinib can be decreased when combined with Boceprevir. Bosentan The metabolism of Brigatinib can be increased when combined with Bosentan. Bosutinib The metabolism of Brigatinib can be decreased when combined with Bosutinib. Brentuximab vedotin The metabolism of Brigatinib can be decreased when combined with Brentuximab vedotin. Budesonide The metabolism of Brigatinib can be increased when combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Bupivacaine. Buprenorphine The metabolism of Brigatinib can be decreased when combined with Buprenorphine. Butacaine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Butacaine. Butalbital The metabolism of Brigatinib can be increased when combined with Butalbital. Butamben The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Butamben. Cabazitaxel The metabolism of Brigatinib can be decreased when combined with Cabazitaxel. Cabozantinib The metabolism of Brigatinib can be decreased when combined with Cabozantinib. Caffeine Caffeine may decrease the excretion rate of Brigatinib which could result in a higher serum level. Calcitriol The metabolism of Brigatinib can be increased when combined with Calcitriol. Canakinumab The metabolism of Brigatinib can be increased when combined with Canakinumab. Candesartan cilexetil The metabolism of Brigatinib can be decreased when combined with Candesartan cilexetil. Candicidin The metabolism of Brigatinib can be decreased when combined with Candicidin. Cannabidiol The metabolism of Brigatinib can be decreased when combined with Cannabidiol. Capmatinib The serum concentration of Capmatinib can be decreased when it is combined with Brigatinib. Capsaicin The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Capsaicin. Carbamazepine The metabolism of Brigatinib can be increased when combined with Carbamazepine. Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Brigatinib. Cefradine The metabolism of Brigatinib can be increased when combined with Cefradine. Celecoxib The metabolism of Brigatinib can be decreased when combined with Celecoxib. Cenobamate The serum concentration of Brigatinib can be decreased when it is combined with Cenobamate. Cephalexin The metabolism of Brigatinib can be decreased when combined with Cephalexin. Ceritinib The metabolism of Brigatinib can be decreased when combined with Ceritinib. Cerivastatin The metabolism of Brigatinib can be increased when combined with Cerivastatin. Certolizumab pegol The metabolism of Brigatinib can be increased when combined with Certolizumab pegol. Chloramphenicol The metabolism of Brigatinib can be decreased when combined with Chloramphenicol. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Chloroprocaine. Chloroquine The metabolism of Brigatinib can be decreased when combined with Chloroquine. Chlorpromazine The metabolism of Brigatinib can be increased when combined with Chlorpromazine. Cholesterol Cholesterol may increase the excretion rate of Brigatinib which could result in a lower serum level and potentially a reduction in efficacy. Cimetidine The metabolism of Brigatinib can be decreased when combined with Cimetidine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Cinchocaine. Ciprofloxacin The metabolism of Brigatinib can be decreased when combined with Ciprofloxacin. Cisapride The metabolism of Brigatinib can be decreased when combined with Cisapride. Citalopram The metabolism of Brigatinib can be decreased when combined with Citalopram. You Might Also Read Methylprednisolone, Uses, Dosage, Side Effect, Interactions, Pregnancy Clarithromycin The metabolism of Brigatinib can be decreased when combined with Clarithromycin. Clevidipine The metabolism of Brigatinib can be increased when combined with Clevidipine. Clindamycin The metabolism of Clindamycin can be increased when combined with Brigatinib. Clobazam The metabolism of Brigatinib can be increased when combined with Clobazam. Clobetasol The metabolism of Brigatinib can be increased when combined with Clobetasol propionate. Clofarabine Brigatinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Clofazimine The metabolism of Brigatinib can be decreased when combined with Clofazimine. Clofibrate The metabolism of Brigatinib can be increased when combined with Clofibrate. Clonazepam The metabolism of Clonazepam can be increased when combined with Brigatinib. Clopidogrel The metabolism of Brigatinib can be decreased when combined with Clopidogrel. Clozapine The metabolism of Brigatinib can be increased when combined with Clozapine. Cobicistat The metabolism of Brigatinib can be decreased when combined with Cobicistat. Cobimetinib The metabolism of Brigatinib can be decreased when combined with Cobimetinib. Cocaine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Cocaine. Conivaptan The metabolism of Brigatinib can be decreased when combined with Conivaptan. Conjugated estrogens Brigatinib may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level. Copanlisib Brigatinib may decrease the excretion rate of Copanlisib which could result in a higher serum level. Corticotropin The metabolism of Brigatinib can be increased when combined with Corticotropin. Cortisone acetate The metabolism of Brigatinib can be increased when combined with Cortisone acetate. Crizotinib The metabolism of Brigatinib can be decreased when combined with Crizotinib. Curcumin The metabolism of Brigatinib can be decreased when combined with Curcumin. Cyclophosphamide The metabolism of Brigatinib can be increased when combined with Cyclophosphamide. Cyclosporine The metabolism of Brigatinib can be decreased when combined with Cyclosporine. Cyproterone acetate The metabolism of Brigatinib can be decreased when combined with Cyproterone acetate. Dabrafenib The serum concentration of Brigatinib can be decreased when it is combined with Dabrafenib. Daclatasvir Daclatasvir may decrease the excretion rate of Brigatinib which could result in a higher serum level. Dacomitinib The metabolism of Brigatinib can be decreased when combined with Dacomitinib. Dactinomycin Brigatinib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Dalfopristin The metabolism of Brigatinib can be decreased when combined with Dalfopristin. Danazol The metabolism of Brigatinib can be decreased when combined with Danazol. Dapsone The metabolism of Brigatinib can be decreased when combined with Dapsone. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Brigatinib. Darolutamide The serum concentration of Brigatinib can be increased when it is combined with Darolutamide. Darunavir The serum concentration of Brigatinib can be increased when it is combined with Darunavir. Dasabuvir The metabolism of Brigatinib can be decreased when combined with Dasabuvir. Dasatinib The metabolism of Brigatinib can be decreased when combined with Dasatinib. Daunorubicin The metabolism of Brigatinib can be decreased when combined with Daunorubicin. Deferasirox The metabolism of Brigatinib can be increased when combined with Deferasirox. Deflazacort The metabolism of Brigatinib can be increased when combined with Deflazacort. Delafloxacin Brigatinib may decrease the excretion rate of Delafloxacin which could result in a higher serum level. Delavirdine The metabolism of Brigatinib can be decreased when combined with Delavirdine. Desipramine The metabolism of Brigatinib can be decreased when combined with Desipramine. Desvenlafaxine The metabolism of Brigatinib can be decreased when combined with Desvenlafaxine. Dexamethasone The metabolism of Brigatinib can be increased when combined with Dexamethasone. Dexamethasone acetate The metabolism of Brigatinib can be increased when combined with Dexamethasone acetate. Dexibuprofen The metabolism of Brigatinib can be decreased when combined with Dexibuprofen. Dextropropoxyphene The metabolism of Brigatinib can be decreased when combined with Dextropropoxyphene. Diclofenac The metabolism of Brigatinib can be decreased when combined with Diclofenac. Dicloxacillin The metabolism of Brigatinib can be increased when combined with Dicloxacillin. Diethylstilbestrol The metabolism of Brigatinib can be decreased when combined with Diethylstilbestrol. Difluocortolone The metabolism of Brigatinib can be increased when combined with Difluocortolone. Dihydroergocornine The metabolism of Brigatinib can be decreased when combined with Dihydroergocornine. Dihydroergocristine The metabolism of Brigatinib can be decreased when combined with Dihydroergocristine. Dihydroergotamine The metabolism of Brigatinib can be decreased when combined with Dihydroergotamine. Diltiazem The metabolism of Brigatinib can be decreased when combined with Diltiazem. Dimethyl sulfoxide The metabolism of Brigatinib can be decreased when combined with Dimethyl sulfoxide. Diosmin The metabolism of Brigatinib can be decreased when combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Diphenhydramine. Docetaxel The metabolism of Brigatinib can be decreased when combined with Docetaxel. Dolutegravir Brigatinib may decrease the excretion rate of Dolutegravir which could result in a higher serum level. Domperidone The metabolism of Brigatinib can be decreased when combined with Domperidone. Donepezil Brigatinib may decrease the excretion rate of Donepezil which could result in a higher serum level. Doxazosin The metabolism of Brigatinib can be decreased when combined with Doxazosin. Doxorubicin The metabolism of Brigatinib can be decreased when combined with Doxorubicin. Dronedarone The serum concentration of Brigatinib can be increased when it is combined with Dronedarone. Drospirenone The metabolism of Brigatinib can be decreased when combined with Drospirenone. Duvelisib The metabolism of Brigatinib can be decreased when combined with Duvelisib. Dyclonine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Dyclonine. Ebastine The metabolism of Brigatinib can be decreased when combined with Ebastine. Echinacea The metabolism of Brigatinib can be increased when combined with Echinacea. Efavirenz The metabolism of Brigatinib can be decreased when combined with Efavirenz. Elagolix The metabolism of Brigatinib can be decreased when combined with Elagolix. Elbasvir Elbasvir may decrease the excretion rate of Brigatinib which could result in a higher serum level. Elexacaftor The metabolism of Brigatinib can be decreased when combined with Elexacaftor. Eltrombopag The metabolism of Brigatinib can be decreased when combined with Eltrombopag. Elvitegravir The metabolism of Brigatinib can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Brigatinib can be increased when combined with Emapalumab. Emtricitabine The excretion of Emtricitabine can be decreased when combined with Brigatinib. Enasidenib The metabolism of Brigatinib can be increased when combined with Enasidenib. Enzalutamide The serum concentration of Brigatinib can be decreased when it is combined with Enzalutamide. Epinephrine The metabolism of Brigatinib can be decreased when combined with Epinephrine. Ergotamine The metabolism of Brigatinib can be decreased when combined with Ergotamine. Erlotinib The serum concentration of Erlotinib can be decreased when it is combined with Brigatinib. Ertugliflozin Brigatinib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level. Erythromycin The metabolism of Brigatinib can be decreased when combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Brigatinib. Esketamine The metabolism of Brigatinib can be increased when combined with Esketamine. Eslicarbazepine The metabolism of Brigatinib can be increased when combined with Eslicarbazepine. Eslicarbazepine acetate The metabolism of Brigatinib can be increased when combined with Eslicarbazepine acetate. Estetrol The metabolism of Brigatinib can be decreased when combined with Estetrol. Estradiol The metabolism of Brigatinib can be decreased when combined with Estradiol. Estradiol acetate The metabolism of Brigatinib can be increased when combined with Estradiol acetate. Estradiol benzoate The metabolism of Brigatinib can be increased when combined with Estradiol benzoate. Estradiol cypionate The metabolism of Brigatinib can be increased when combined with Estradiol cypionate. Estradiol dienanthate The metabolism of Brigatinib can be increased when combined with Estradiol dienanthate. Estradiol valerate The metabolism of Brigatinib can be increased when combined with Estradiol valerate. Estrone sulfate The excretion of Estrone sulfate can be decreased when combined with Brigatinib. Eszopiclone The serum concentration of Eszopiclone can be decreased when it is combined with Brigatinib. Etanercept The metabolism of Brigatinib can be increased when combined with Etanercept Ethanol The metabolism of Brigatinib can be increased when combined with Ethanol. Ethinylestradiol The metabolism of Brigatinib can be decreased when combined with Ethinylestradiol. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Etidocaine. Etoposide Brigatinib may decrease the excretion rate of Etoposide which could result in a higher serum level. Etoricoxib The metabolism of Brigatinib can be decreased when combined with Etoricoxib. Etravirine The metabolism of Brigatinib can be increased when combined with Etravirine. Ezetimibe Brigatinib may decrease the excretion rate of Ezetimibe which could result in a higher serum level. Favipiravir The metabolism of Brigatinib can be decreased when combined with Favipiravir. Febuxostat The excretion of Brigatinib can be decreased when combined with Febuxostat. Fedratinib Fedratinib may decrease the excretion rate of Brigatinib which could result in a higher serum level. Felbamate The metabolism of Brigatinib can be increased when combined with Felbamate. Felodipine The metabolism of Brigatinib can be decreased when combined with Felodipine. Fenofibrate The metabolism of Brigatinib can be decreased when combined with Fenofibrate. Fexinidazole The metabolism of Brigatinib can be decreased when combined with Fexinidazole. Finerenone The metabolism of Brigatinib can be decreased when combined with Finerenone. Flecainide The excretion of Flecainide can be decreased when combined with Brigatinib. Flucloxacillin The metabolism of Brigatinib can be increased when combined with Flucloxacillin. Fluconazole The metabolism of Brigatinib can be decreased when combined with Fluconazole. Flunisolide The metabolism of Brigatinib can be increased when combined with Flunisolide. Fluocinolone The metabolism of Brigatinib can be increased when combined with Fluocinolone acetonide. Fluocinonide The metabolism of Brigatinib can be increased when combined with Fluocinonide. Fluocortolone The metabolism of Brigatinib can be increased when combined with Fluocortolone. Fluorouracil The metabolism of Brigatinib can be decreased when combined with Fluorouracil. Fluoxetine The metabolism of Brigatinib can be decreased when combined with Fluoxetine. Fluticasone The metabolism of Brigatinib can be increased when combined with Fluticasone. Fluticasone furoate The metabolism of Brigatinib can be increased when combined with Fluticasone furoate. Fluticasone propionate The metabolism of Brigatinib can be decreased when combined with Fluticasone propionate. Fluvastatin The metabolism of Brigatinib can be decreased when combined with Fluvastatin. Fluvoxamine The metabolism of Brigatinib can be decreased when combined with Fluvoxamine. Folic acid Brigatinib may decrease the excretion rate of Folic acid which could result in a higher serum level. Follitropin The therapeutic efficacy of Follitropin can be decreased when used in combination with Brigatinib. Formestane The metabolism of Brigatinib can be increased when combined with Formestane. Fosamprenavir The metabolism of Brigatinib can be decreased when combined with Fosamprenavir. Fosaprepitant The metabolism of Brigatinib can be increased when combined with Fosaprepitant. Fosnetupitant The metabolism of Brigatinib can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Brigatinib can be increased when combined with Fosphenytoin. Fostamatinib The metabolism of Brigatinib can be decreased when combined with Fostamatinib. Fostemsavir Fostemsavir may decrease the excretion rate of Brigatinib which could result in a higher serum level. Fusidic acid The metabolism of Brigatinib can be decreased when combined with Fusidic acid. Ganciclovir The excretion of Ganciclovir can be decreased when combined with Brigatinib. Gefitinib Gefitinib may decrease the excretion rate of Brigatinib which could result in a higher serum level. Gemfibrozil The metabolism of Brigatinib can be decreased when combined with Gemfibrozil. Gilteritinib The metabolism of Brigatinib can be decreased when combined with Gilteritinib. Ginkgo biloba The metabolism of Brigatinib can be decreased when combined with Ginkgo biloba. Glasdegib The metabolism of Brigatinib can be decreased when combined with Glasdegib. Glecaprevir The metabolism of Brigatinib can be decreased when combined with Glecaprevir. Glyburide The metabolism of Brigatinib can be decreased when combined with Glyburide. Glycerol phenylbutyrate The metabolism of Brigatinib can be increased when combined with Glycerol phenylbutyrate. Golimumab The metabolism of Brigatinib can be increased when combined with Golimumab. Grazoprevir Grazoprevir may decrease the excretion rate of Brigatinib which could result in a higher serum level. Griseofulvin The metabolism of Brigatinib can be increased when combined with Griseofulvin. Guanidine The excretion of Guanidine can be decreased when combined with Brigatinib. Halofantrine The metabolism of Brigatinib can be decreased when combined with Halofantrine. Haloperidol The serum concentration of Haloperidol can be increased when it is combined with Brigatinib. Hydralazine The metabolism of Brigatinib can be decreased when combined with Hydralazine. Hydrocortamate The metabolism of Brigatinib can be increased when combined with Hydrocortamate. Hydrocortisone The metabolism of Brigatinib can be increased when combined with Hydrocortisone. Hydrocortisone acetate The metabolism of Brigatinib can be increased when combined with Hydrocortisone acetate. Hydrocortisone butyrate The metabolism of Brigatinib can be increased when combined with Hydrocortisone butyrate. Hydrocortisone succinate The metabolism of Brigatinib can be increased when combined with Hydrocortisone succinate. Hydroxychloroquine The metabolism of Brigatinib can be decreased when combined with Hydroxychloroquine. Ibuprofen The metabolism of Brigatinib can be decreased when combined with Ibuprofen. Idelalisib The metabolism of Brigatinib can be decreased when combined with Idelalisib. Ifosfamide The metabolism of Ifosfamide can be increased when combined with Brigatinib. Imatinib The serum concentration of Brigatinib can be increased when it is combined with Imatinib. Indinavir The metabolism of Brigatinib can be decreased when combined with Indinavir. Infigratinib The metabolism of Brigatinib can be decreased when combined with Infigratinib. Infliximab The metabolism of Brigatinib can be increased when combined with Infliximab. Irbesartan The metabolism of Brigatinib can be decreased when combined with Irbesartan. Irinotecan Brigatinib may decrease the excretion rate of Irinotecan which could result in a higher serum level. Isavuconazole The metabolism of Brigatinib can be increased when combined with Isavuconazole. Isavuconazonium The metabolism of Brigatinib can be increased when combined with Isavuconazonium. Isoniazid The metabolism of Brigatinib can be decreased when combined with Isoniazid. Isradipine The metabolism of Brigatinib can be decreased when combined with Isradipine. Istradefylline The metabolism of Brigatinib can be decreased when combined with Istradefylline. Itraconazole The metabolism of Brigatinib can be decreased when combined with Itraconazole. Ivacaftor The metabolism of Brigatinib can be decreased when combined with Ivacaftor. Ivermectin Brigatinib may decrease the excretion rate of Ivermectin which could result in a higher serum level. Ivosidenib The metabolism of Brigatinib can be increased when combined with Ivosidenib. Ketamine The metabolism of Brigatinib can be decreased when combined with Ketamine. Ketazolam The metabolism of Brigatinib can be decreased when combined with Ketazolam. Ketoconazole The metabolism of Brigatinib can be decreased when combined with Ketoconazole. Ketoprofen The metabolism of Brigatinib can be decreased when combined with Ketoprofen. Ketorolac The metabolism of Brigatinib can be decreased when combined with Ketorolac. Lacosamide The metabolism of Brigatinib can be decreased when combined with Lacosamide. Lamivudine Brigatinib may decrease the excretion rate of Lamivudine which could result in a higher serum level. Lanreotide The metabolism of Brigatinib can be decreased when combined with Lanreotide. Lansoprazole The metabolism of Brigatinib can be decreased when combined with Lansoprazole. Lapatinib The metabolism of Brigatinib can be decreased when combined with Lapatinib. Lasmiditan The serum concentration of Brigatinib can be increased when it is combined with Lasmiditan. Ledipasvir Ledipasvir may decrease the excretion rate of Brigatinib which could result in a higher serum level. Lefamulin The serum concentration of Brigatinib can be increased when it is combined with Lefamulin. Leflunomide Brigatinib may decrease the excretion rate of Leflunomide which could result in a higher serum level. Lemborexant The serum concentration of Lemborexant can be decreased when it is combined with Brigatinib. Lenvatinib Brigatinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level. Lesinurad The metabolism of Brigatinib can be increased when combined with Lesinurad. Letermovir The metabolism of Brigatinib can be decreased when combined with Letermovir. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Levobupivacaine. You Might Also Read Ceftazidime; Indications, Dosage, Side Effects, Interactions Levofloxacin The excretion of Levofloxacin can be decreased when combined with Brigatinib. Levoketoconazole The metabolism of Brigatinib can be decreased when combined with Levoketoconazole. Levomilnacipran The metabolism of Levomilnacipran can be increased when combined with Brigatinib. Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Brigatinib. Lidocaine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Lidocaine. Linagliptin The metabolism of Brigatinib can be decreased when combined with Linagliptin. Linzagolix The serum concentration of Brigatinib can be increased when it is combined with Linzagolix. Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Brigatinib. Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Brigatinib. Lomitapide The metabolism of Brigatinib can be decreased when combined with Lomitapide. Lonafarnib The metabolism of Brigatinib can be decreased when combined with Lonafarnib. Loperamide The metabolism of Brigatinib can be decreased when combined with Loperamide. Lopinavir The metabolism of Brigatinib can be decreased when combined with Lopinavir. Loratadine The metabolism of Brigatinib can be decreased when combined with Loratadine. Lorlatinib The metabolism of Brigatinib can be increased when combined with Lorlatinib. Losartan The metabolism of Brigatinib can be decreased when combined with Losartan. Lovastatin The metabolism of Brigatinib can be decreased when combined with Lovastatin. Lumacaftor The metabolism of Brigatinib can be increased when combined with Lumacaftor. Lumateperone The serum concentration of Lumateperone can be decreased when it is combined with Brigatinib. Lusutrombopag Brigatinib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level. Manidipine The metabolism of Brigatinib can be decreased when combined with Manidipine. Maribavir Maribavir may decrease the excretion rate of Brigatinib which could result in a higher serum level. Mavacamten The serum concentration of Brigatinib can be decreased when it is combined with Mavacamten. Medroxyprogesterone The metabolism of Brigatinib can be increased when combined with Medroxyprogesterone acetate. Meloxicam The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Meloxicam. Meperidine The metabolism of Brigatinib can be decreased when combined with Meperidine. Mephenytoin The metabolism of Brigatinib can be decreased when combined with Mephenytoin. Mepivacaine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Mepivacaine. Meprednisone The metabolism of Brigatinib can be increased when combined with Meprednisone. Mestranol The metabolism of Brigatinib can be decreased when combined with Mestranol. Metformin The excretion of Metformin can be decreased when combined with Brigatinib. Methadone The metabolism of Brigatinib can be decreased when combined with Methadone. Methimazole The metabolism of Brigatinib can be decreased when combined with Methimazole. Methotrexate Brigatinib may decrease the excretion rate of Methotrexate which could result in a higher serum level. Methoxy polyethylene The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Brigatinib. Methylene blue The metabolism of Brigatinib can be decreased when combined with Methylene blue. Methylergometrine The metabolism of Brigatinib can be decreased when combined with Methylergometrine. Methylphenobarbital The metabolism of Brigatinib can be increased when combined with Methylphenobarbital. Methylprednisolone The metabolism of Brigatinib can be increased when combined with Methylprednisolone. Methylprednisone The metabolism of Brigatinib can be decreased when combined with Methylprednisone. Methysergide The metabolism of Brigatinib can be decreased when combined with Methysergide. Metreleptin The metabolism of Brigatinib can be increased when combined with Metreleptin. Metronidazole The metabolism of Brigatinib can be decreased when combined with Metronidazole. Metyrapone The metabolism of Brigatinib can be increased when combined with Metyrapone. Miconazole The metabolism of Brigatinib can be decreased when combined with Miconazole. Midazolam The metabolism of Brigatinib can be decreased when combined with Midazolam. Midostaurin The metabolism of Brigatinib can be decreased when combined with Midostaurin. Mifepristone The serum concentration of Brigatinib can be increased when it is combined with Mifepristone. Milnacipran The metabolism of Milnacipran can be increased when combined with Brigatinib. Miocamycin The metabolism of Brigatinib can be decreased when combined with Miocamycin. Mirtazapine The metabolism of Brigatinib can be decreased when combined with Mirtazapine. Mitapivat The metabolism of Brigatinib can be increased when combined with Mitapivat. Mitotane The metabolism of Brigatinib can be increased when combined with Mitotane. Mitoxantrone Brigatinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level. Mobocertinib The serum concentration of Brigatinib can be decreased when it is combined with Mobocertinib. Modafinil The metabolism of Brigatinib can be increased when combined with Modafinil. Mometasone furoate The metabolism of Brigatinib can be increased when combined with Mometasone furoate. Montelukast The metabolism of Brigatinib can be decreased when combined with Montelukast. Morphine The metabolism of Brigatinib can be decreased when combined with Morphine. Mosunetuzumab The metabolism of Brigatinib can be decreased when combined with Mosunetuzumab. Mycophenolate mofetil The metabolism of Brigatinib can be decreased when combined with Mycophenolate mofetil. Nadolol The excretion of Nadolol can be decreased when combined with Brigatinib. Nafcillin The metabolism of Brigatinib can be increased when combined with Nafcillin. Naloxone The metabolism of Brigatinib can be decreased when combined with Naloxone. Naproxen The metabolism of Brigatinib can be decreased when combined with Naproxen. Nefazodone The metabolism of Brigatinib can be decreased when combined with Nefazodone. Nelfinavir The metabolism of Brigatinib can be decreased when combined with Nelfinavir. Netupitant The metabolism of Brigatinib can be decreased when combined with Netupitant. Niacin The metabolism of Brigatinib can be decreased when combined with Niacin. Nicardipine The metabolism of Brigatinib can be decreased when combined with Nicardipine. Nilotinib The metabolism of Brigatinib can be decreased when combined with Nilotinib. Nilutamide The metabolism of Brigatinib can be decreased when combined with Nilutamide. Nilvadipine The metabolism of Brigatinib can be decreased when combined with Nilvadipine. Nintedanib The metabolism of Brigatinib can be decreased when combined with Nintedanib. Nitrofurantoin Brigatinib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. Norethisterone The metabolism of Brigatinib can be decreased when combined with Norethisterone. Norgestimate The metabolism of Brigatinib can be increased when combined with Norgestimate. Noscapine The metabolism of Brigatinib can be decreased when combined with Noscapine. Novobiocin Novobiocin may decrease the excretion rate of Brigatinib which could result in a higher serum level. Octreotide The serum concentration of Brigatinib can be increased when it is combined with Octreotide. Olaparib The metabolism of Brigatinib can be decreased when combined with Olaparib. Oliceridine The serum concentration of Oliceridine can be decreased when it is combined with Brigatinib. Olodaterol The metabolism of Brigatinib can be decreased when combined with Olodaterol. Ombitasvir The metabolism of Brigatinib can be decreased when combined with Ombitasvir. Omeprazole The metabolism of Brigatinib can be increased when combined with Omeprazole. Oritavancin The metabolism of Brigatinib can be increased when combined with Oritavancin. Orphenadrine The metabolism of Brigatinib can be decreased when combined with Orphenadrine. Osilodrostat The metabolism of Brigatinib can be decreased when combined with Osilodrostat. Osimertinib The metabolism of Brigatinib can be decreased when combined with Osimertinib. Oteseconazole The serum concentration of Brigatinib can be increased when it is combined with Oteseconazole. Oxaliplatin Brigatinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. Oxcarbazepine The metabolism of Brigatinib can be increased when combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Oxybuprocaine. Oxybutynin The metabolism of Brigatinib can be decreased when combined with Oxybutynin. Ozanimod Brigatinib may decrease the excretion rate of Ozanimod which could result in a higher serum level. Paclitaxel The metabolism of Brigatinib can be increased when combined with Paclitaxel. Pacritinib The serum concentration of Brigatinib can be increased when it is combined with Pacritinib. Palbociclib The metabolism of Brigatinib can be decreased when combined with Palbociclib. Pantoprazole Pantoprazole may decrease the excretion rate of Brigatinib which could result in a higher serum level. Paritaprevir Paritaprevir may decrease the excretion rate of Brigatinib which could result in a higher serum level. Pasireotide The metabolism of Brigatinib can be decreased when combined with Pasireotide. Pazopanib The metabolism of Brigatinib can be decreased when combined with Pazopanib. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Brigatinib. Pentobarbital The metabolism of Brigatinib can be increased when combined with Pentobarbital. Perampanel The metabolism of Perampanel can be increased when combined with Brigatinib. Phenobarbital The metabolism of Brigatinib can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Phenol. Phenprocoumon The metabolism of Brigatinib can be decreased when combined with Phenprocoumon. Phenylbutazone The metabolism of Brigatinib can be increased when combined with Phenylbutazone. Phenytoin The metabolism of Brigatinib can be increased when combined with Phenytoin. Pibrentasvir Brigatinib may decrease the excretion rate of Pibrentasvir which could result in a higher serum level. Pimavanserin The metabolism of Brigatinib can be decreased when combined with Pimavanserin. Pimozide The metabolism of Brigatinib can be decreased when combined with Pimozide. Pioglitazone The metabolism of Brigatinib can be decreased when combined with Pioglitazone. Piperaquine The metabolism of Brigatinib can be decreased when combined with Piperaquine. Piroxicam The metabolism of Brigatinib can be decreased when combined with Piroxicam. Pitavastatin The metabolism of Brigatinib can be decreased when combined with Pitavastatin. Pitolisant The serum concentration of Brigatinib can be decreased when it is combined with Pitolisant. Ponatinib The metabolism of Brigatinib can be decreased when combined with Ponatinib. Posaconazole The metabolism of Brigatinib can be decreased when combined with Posaconazole. Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Brigatinib. Potassium perchlorate The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Brigatinib. Pralatrexate Brigatinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pralsetinib The metabolism of Brigatinib can be increased when combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Pramocaine. Pravastatin Pravastatin may decrease the excretion rate of Brigatinib which could result in a higher serum level. Prazosin Brigatinib may decrease the excretion rate of Prazosin which could result in a higher serum level. Prednisolone The metabolism of Brigatinib can be increased when combined with Prednisolone. Prednisolone acetate The metabolism of Brigatinib can be increased when combined with Prednisolone acetate. Prednisolone phosphate The metabolism of Brigatinib can be increased when combined with Prednisolone phosphate. Prednisone acetate The metabolism of Brigatinib can be increased when combined with Prednisone acetate. Pretomanid The metabolism of Brigatinib can be decreased when combined with Pretomanid. Prilocaine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Prilocaine. Primaquine The metabolism of Brigatinib can be decreased when combined with Primaquine. Primidone The metabolism of Brigatinib can be increased when combined with Primidone. Probenecid The metabolism of Brigatinib can be increased when combined with Probenecid. Procainamide The excretion of Procainamide can be decreased when combined with Brigatinib. Procaine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Procaine. Progesterone Progesterone may decrease the excretion rate of Brigatinib which could result in a higher serum level. Proparacaine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Proparacaine. Propofol The metabolism of Brigatinib can be decreased when combined with Propofol. Propoxycaine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Propoxycaine. Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Brigatinib. Protirelin The therapeutic efficacy of Protirelin can be decreased when used in combination with Brigatinib. Pyrimethamine The metabolism of Brigatinib can be decreased when combined with Pyrimethamine. Quinidine The metabolism of Brigatinib can be decreased when combined with Quinidine. Quinine The metabolism of Brigatinib can be increased when combined with Quinine. Quinupristin The metabolism of Brigatinib can be decreased when combined with Quinupristin. Rabeprazole Rabeprazole may decrease the excretion rate of Brigatinib which could result in a higher serum level. Raloxifene The metabolism of Brigatinib can be decreased when combined with Raloxifene. Ranolazine The metabolism of Ranolazine can be increased when combined with Brigatinib. Regorafenib Regorafenib may decrease the excretion rate of Brigatinib which could result in a higher serum level. Relebactam The excretion of Relebactam can be decreased when combined with Brigatinib. Remdesivir The metabolism of Brigatinib can be decreased when combined with Remdesivir. Repaglinide The metabolism of Brigatinib can be decreased when combined with Repaglinide. Retapamulin The metabolism of Retapamulin can be increased when combined with Brigatinib. Revefenacin Brigatinib may decrease the excretion rate of Revefenacin which could result in a higher serum level. Ribociclib The metabolism of Brigatinib can be decreased when combined with Ribociclib. Rifabutin The metabolism of Brigatinib can be increased when combined with Rifabutin. Rifampicin The metabolism of Brigatinib can be increased when combined with Rifampicin. Rifamycin The metabolism of Brigatinib can be increased when combined with Rifamycin. Rifapentine The metabolism of Brigatinib can be increased when combined with Rifapentine. Rilonacept The metabolism of Brigatinib can be increased when combined with Rilonacept. Rilpivirine The serum concentration of Rilpivirine can be decreased when it is combined with Brigatinib. Riluzole Brigatinib may decrease the excretion rate of Riluzole which could result in a higher serum level. Rimegepant The metabolism of Rimegepant can be increased when combined with Brigatinib. Riociguat The metabolism of Brigatinib can be decreased when combined with Riociguat. Ripretinib Brigatinib may decrease the excretion rate of Ripretinib which could result in a higher serum level. Ritonavir The metabolism of Brigatinib can be decreased when combined with Ritonavir. Rivaroxaban Brigatinib may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. Rofecoxib The metabolism of Brigatinib can be increased when combined with Rofecoxib. Roflumilast The metabolism of Brigatinib can be decreased when combined with Roflumilast. Rolapitant Rolapitant may decrease the excretion rate of Brigatinib which could result in a higher serum level. Ropivacaine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Ropivacaine. Rosiglitazone The metabolism of Brigatinib can be decreased when combined with Rosiglitazone. Rosuvastatin The metabolism of Brigatinib can be decreased when combined with Rosuvastatin. Roxadustat The serum concentration of Brigatinib can be increased when it is combined with Roxadustat. Roxithromycin The metabolism of Brigatinib can be decreased when combined with Roxithromycin. Rucaparib The metabolism of Brigatinib can be decreased when combined with Rucaparib. Rufinamide The metabolism of Brigatinib can be increased when combined with Rufinamide. Safinamide Safinamide may decrease the excretion rate of Brigatinib which could result in a higher serum level. Salmeterol The metabolism of Brigatinib can be decreased when combined with Salmeterol. Salmon calcitonin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Brigatinib. Saquinavir The metabolism of Brigatinib can be decreased when combined with Saquinavir. Sarilumab The metabolism of Brigatinib can be increased when combined with Sarilumab. Satralizumab The serum concentration of Brigatinib can be decreased when it is combined with Satralizumab. Secobarbital The metabolism of Brigatinib can be increased when combined with Secobarbital. Secukinumab The metabolism of Brigatinib can be increased when combined with Secukinumab. Segesterone acetate The metabolism of Segesterone acetate can be increased when combined with Brigatinib. Selegiline The metabolism of Brigatinib can be decreased when combined with Selegiline. Selexipag The metabolism of Brigatinib can be decreased when combined with Selexipag. Selpercatinib The serum concentration of Selpercatinib can be decreased when it is combined with Brigatinib. Selumetinib The metabolism of Brigatinib can be decreased when combined with Selumetinib. Siltuximab The metabolism of Brigatinib can be increased when combined with Siltuximab. Simeprevir The metabolism of Brigatinib can be decreased when combined with Simeprevir. Simvastatin The metabolism of Brigatinib can be decreased when combined with Simvastatin. Siponimod The metabolism of Brigatinib can be decreased when combined with Siponimod. You Might Also Read Lepargylic Acid - Indications, Contraindications Sitagliptin The metabolism of Brigatinib can be decreased when combined with Sitagliptin. Sitaxentan The metabolism of Brigatinib can be decreased when combined with Sitaxentan. Sofosbuvir Brigatinib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. Solriamfetol The excretion of Solriamfetol can be decreased when combined with Brigatinib. Somatostatin The metabolism of Brigatinib can be decreased when combined with Somatostatin. Somatrogon The metabolism of Brigatinib can be increased when combined with Somatrogon. Sorafenib The metabolism of Brigatinib can be decreased when combined with Sorafenib. Sotagliflozin Sotagliflozin may decrease the excretion rate of Brigatinib which could result in a higher serum level. Sotorasib The serum concentration of Brigatinib can be decreased when it is combined with Sotorasib. Spironolactone The metabolism of Brigatinib can be decreased when combined with Spironolactone. St. John’s Wort The metabolism of Brigatinib can be increased when combined with St. John’s Wort. Stiripentol The metabolism of Brigatinib can be decreased when combined with Stiripentol. Sulfadiazine The metabolism of Brigatinib can be decreased when combined with Sulfadiazine. Sulfamethoxazole The metabolism of Brigatinib can be decreased when combined with Sulfamethoxazole. Sulfaphenazole The metabolism of Brigatinib can be decreased when combined with Sulfaphenazole. Sulfasalazine Sulfasalazine may decrease the excretion rate of Brigatinib which could result in a higher serum level. Sulfinpyrazone The metabolism of Brigatinib can be increased when combined with Sulfinpyrazone. Sumatriptan Brigatinib may decrease the excretion rate of Sumatriptan which could result in a higher serum level. Sunitinib Sunitinib may decrease the excretion rate of Brigatinib which could result in a higher serum level. Suvorexant The metabolism of Brigatinib can be decreased when combined with Suvorexant. Tacrolimus The metabolism of Brigatinib can be decreased when combined with Tacrolimus. Tafamidis The serum concentration of Brigatinib can be increased when it is combined with Tafamidis. Talazoparib Brigatinib may decrease the excretion rate of Talazoparib which could result in a higher serum level. Tamoxifen The metabolism of Brigatinib can be increased when combined with Tamoxifen. Tasimelteon The metabolism of Brigatinib can be decreased when combined with Tasimelteon. Taurocholic acid Taurocholic acid may decrease the excretion rate of Brigatinib which could result in a higher serum level. Tazarotene The metabolism of Brigatinib can be decreased when combined with Tazarotene. Tazemetostat The metabolism of Brigatinib can be decreased when combined with Tazemetostat. Tecovirimat The metabolism of Brigatinib can be increased when combined with Tecovirimat. Tegafur The metabolism of Brigatinib can be decreased when combined with Tegafur. Tegaserod The metabolism of Brigatinib can be decreased when combined with Tegaserod. Telaprevir The metabolism of Brigatinib can be decreased when combined with Telaprevir. Telithromycin The metabolism of Brigatinib can be decreased when combined with Telithromycin. Telmisartan Telmisartan may decrease the excretion rate of Brigatinib which could result in a higher serum level. Telotristat ethyl The serum concentration of Brigatinib can be decreased when it is combined with Telotristat ethyl. Teniposide The metabolism of Brigatinib can be decreased when combined with Teniposide. Tenofovir alafenamide The serum concentration of Tenofovir alafenamide can be increased when it is combined with Brigatinib. Tepotinib Tepotinib may decrease the excretion rate of Brigatinib which could result in a higher serum level. Terbinafine The metabolism of Brigatinib can be increased when combined with Terbinafine. Terfenadine The metabolism of Brigatinib can be decreased when combined with Terfenadine. Teriflunomide The metabolism of Brigatinib can be decreased when combined with Teriflunomide. Teriparatide The therapeutic efficacy of Teriparatide can be decreased when used in combination with Brigatinib. Testosterone The metabolism of Brigatinib can be increased when combined with Testosterone. Testosterone cypionate The metabolism of Brigatinib can be decreased when combined with Testosterone cypionate. Testosterone The metabolism of Brigatinib can be decreased when combined with Testosterone enanthate. Tetracaine The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Tetracaine. Tetracycline The metabolism of Brigatinib can be decreased when combined with Tetracycline. Theophylline The metabolism of Brigatinib can be decreased when combined with Theophylline. Thiamylal The metabolism of Brigatinib can be increased when combined with Thiamylal. Thyroid, porcine The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Brigatinib. Thyrotropin alfa The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Brigatinib. Ticagrelor The metabolism of Brigatinib can be decreased when combined with Ticagrelor. Ticlopidine The metabolism of Brigatinib can be decreased when combined with Ticlopidine. Tipranavir The metabolism of Brigatinib can be decreased when combined with Tipranavir. Tivozanib The metabolism of Tivozanib can be increased when combined with Brigatinib. Tocilizumab The metabolism of Brigatinib can be increased when combined with Tocilizumab. Tolbutamide The metabolism of Brigatinib can be decreased when combined with Tolbutamide. Topiramate The metabolism of Brigatinib can be increased when combined with Topiramate. Topotecan The excretion of Topotecan can be decreased when combined with Brigatinib. Torasemide The metabolism of Brigatinib can be decreased when combined with Torasemide. Tramadol The metabolism of Tramadol can be increased when combined with Brigatinib. Trametinib The metabolism of Brigatinib can be decreased when combined with Trametinib. Treprostinil The metabolism of Brigatinib can be decreased when combined with Treprostinil. Tretinoin The metabolism of Brigatinib can be decreased when combined with Tretinoin. Triamcinolone The metabolism of Brigatinib can be increased when combined with Triamcinolone. Triclabendazole The metabolism of Brigatinib can be decreased when combined with Triclabendazole. Trilaciclib Brigatinib may decrease the excretion rate of Trilaciclib which could result in a higher serum level. Trimethadione The metabolism of Brigatinib can be decreased when combined with Trimethadione. Trimethoprim The metabolism of Brigatinib can be decreased when combined with Trimethoprim. Troglitazone The metabolism of Brigatinib can be increased when combined with Troglitazone. Troleandomycin The metabolism of Brigatinib can be decreased when combined with Troleandomycin. Tucatinib The metabolism of Tucatinib can be decreased when combined with Brigatinib. Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Brigatinib. Valproic acid The metabolism of Brigatinib can be decreased when combined with Valproic acid. Vandetanib Vandetanib may decrease the excretion rate of Brigatinib which could result in a higher serum level. Velpatasvir The metabolism of Brigatinib can be decreased when combined with Velpatasvir. Vemurafenib The metabolism of Brigatinib can be increased when combined with Vemurafenib. Venetoclax The metabolism of Brigatinib can be decreased when combined with Venetoclax. Venlafaxine Venlafaxine may increase the excretion rate of Brigatinib which could result in a lower serum level and potentially a reduction in efficacy. Verapamil The metabolism of Brigatinib can be decreased when combined with Verapamil. Viloxazine The metabolism of Brigatinib can be decreased when combined with Viloxazine. Vinblastine The metabolism of Brigatinib can be increased when combined with Vinblastine. Vincristine Brigatinib may decrease the excretion rate of Vincristine which could result in a higher serum level. Vismodegib Vismodegib may decrease the excretion rate of Brigatinib which could result in a higher serum level. Vitamin E The metabolism of Brigatinib can be increased when combined with Vitamin E. Vorapaxar The metabolism of Brigatinib can be decreased when combined with Vorapaxar. Voriconazole The metabolism of Brigatinib can be decreased when combined with Voriconazole. Vortioxetine The metabolism of Brigatinib can be decreased when combined with Vortioxetine. Voxelotor The serum concentration of Brigatinib can be increased when it is combined with Voxelotor. Voxilaprevir The metabolism of Brigatinib can be decreased when combined with Voxilaprevir. Warfarin The metabolism of Warfarin can be increased when combined with Brigatinib. Zafirlukast The metabolism of Brigatinib can be decreased when combined with Zafirlukast. Zidovudine The metabolism of Brigatinib can be decreased when combined with Zidovudine. Zimelidine The metabolism of Brigatinib can be decreased when combined with Zimelidine. Ziprasidone The metabolism of Brigatinib can be decreased when combined with Ziprasidone. Pregnancy and Lactation US FDA pregnancy category: Not assigned. Pregnancy Based on its mechanism of action and findings in animals, brigatinib can cause fetal harm when administered to pregnant women. Based on findings in male reproductive organs in animals, brigatinib may cause reduced fertility in males. Females of reproductive potential are advised to use effective nonhormonal contraception during treatment with brigatinib and for at least 4 months after the final dose. Brigatinib can render some hormonal contraceptives ineffective. Because of the potential for genotoxicity, males with female partners of reproductive potential are advised to use effective contraception during treatment with brigatinib and for at least 3 months after the final dose. Lactation It is unknown if brigatinib is distributed in human breast milk. Because of the potential for adverse reactions in breastfed infants, lactating women are advised not to breastfeed during treatment with brigatinib and for 1 week following the final dose. How should this medicine be used? Brigatinib comes as a tablet to take by mouth. It is usually taken with or without food once daily. Take brigatinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take brigatinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Swallow the tablets whole; do not chew or crush them. If you vomit after taking brigatinib, do not take another dose. Continue your regular dosing schedule. Your doctor may start you on a low dose of brigatinib and increase your dose once after 7 days of treatment. Your doctor may need to temporarily or permanently stop your treatment or decrease your dose of brigatinib or other medications that you are taking, depending on the side effects that you experience during your treatment. Talk to your doctor about how you are feeling during your treatment. Do not stop taking brigatinib without talking to your doctor. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. What special precautions should I follow? Before taking brigatinib, tell your doctor and pharmacist if you are allergic to brigatinib, any other medications, or any of the ingredients in brigatinib tablets. Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: antifungals such as itraconazole (Onmel, Sporanox, Tolsura), ketoconazole, buprenorphine and naloxone (Suboxone), carbamazepine (Equetro, Tegretol, Teril, others), clarithromycin, cyclosporine (Gengraf, Neoral, Sandimmune), diltiazem (Cardizem, Cartia, Diltzac, others), efavirenz (Sustiva, in Atripla, Symfi), erythromycin (E.E.S., Eryc, Erythrocin), indinavir (Crixivan), nefazodone, nelfinavir (Viracept), nevirapine (Viramune), phenobarbital; phenytoin (Dilantin, Phenytek), pioglitazone (Actos, in Actoplus Met, Duetact, Oseni), rifabutin (Mycobutin), rifampin (Rifadin, Rimactane, in Rifamate, in Rifater), ritonavir (Norvir, in Kaletra, Technivie, Viekira), sirolimus (Rapamune), tacrolimus (Astagraf, Envarsus, Prograf), or verapamil (Calan, Verelan, in Tarka). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with brigatinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. tell your doctor what herbal products you are taking, especially St. John’s wort. tell your doctor if you have or have ever had high blood pressure; a slow heartbeat; diabetes or other blood sugar problems; or kidney or liver disease. tell your doctor if you are pregnant, plan to become pregnant, or plan to father a child. Brigatinib may interfere with the action of hormonal contraceptives (birth control pills, patches, rings, implants, or injections), so you should not use these as your only method of birth control during your treatment. You must use a non-hormonal birth control such as a barrier method (device that blocks sperm from entering the uterus such as a condom or a diaphragm). Ask your doctor to help you choose a method of birth control that will work for you. If you are female, you will need to use non-hormonal birth control during your treatment and for 4 months after your final dose. If you are male, you and your female partner should use birth control during your treatment and continue to use birth control for 3 months after your final dose. Brigatinib may harm the fetus. tell your doctor if you are breastfeeding. You should not breastfeed during your treatment with brigatinib and for up to 1 week after your final dose. you should know that this medication may decrease fertility in men. Talk to your doctor about the risks of taking brigatinib. References https://pubchem.ncbi.nlm.nih.gov/compound/Brigatinib https://go.drugbank.com/drugs/DB12267 https://en.wikipedia.org/wiki/Brigatinib https://medlineplus.gov/druginfo/meds/a617016.html https://www.drugs.com/mtm/brigatinib.html https://www.cancer.gov/about-cancer/treatment/drugs/brigatinib ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3545311/ ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads https://www.dgidb.org/drugs/BRIGATINIB DrugBank https://www.drugbank.ca/legal/terms_of_use Brigatinib https://www.drugbank.ca/drugs/DB12267 IUPHAR/BPS Guide to PHARMACOLOGY https://www.guidetopharmacology.org/about.jsp#license https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7741 Guide to Pharmacology Target Classification https://www.guidetopharmacology.org/targets.jsp Therapeutic Target Database (TTD) Brigatinib http://idrblab.net/ttd/data/drug/details/D08PIE ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Brigatinib [USAN:INN] https://chem.nlm.nih.gov/chemidplus/sid/1197953540 ChemIDplus Chemical Information Classification https://chem.nlm.nih.gov/chemidplus/ EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources Brigatinib https://comptox.epa.gov/dashboard/DTXSID501027929 CompTox Chemicals Dashboard Chemical Lists https://comptox.epa.gov/dashboard/chemical-lists/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice https://echa.europa.eu/information-on-chemicals https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/295083 FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking BRIGATINIB https://gsrs.ncats.nih.gov/ginas/app/beta/substances/HYW8DB273J ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ DailyMed LICENSE https://www.nlm.nih.gov/copyright.html BRIGATINIB https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=BRIGATINIB FDA Pharm Classes https://www.fda.gov/about-fda/about-website/website-policies#linking BRIGATINIB https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm FDA Pharmacological Classification https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm LiverTox LICENSE https://www.nlm.nih.gov/copyright.html Brigatinib https://www.ncbi.nlm.nih.gov/books/n/livertox/Brigatinib/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C98831 NCI Thesaurus Tree https://ncit.nci.nih.gov European Medicines Agency (EMA) https://www.ema.europa.eu/en/about-us/legal-notice Alunbrig (EMEA/H/C/004248) https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig Drugs and Lactation Database (LactMed) LICENSE https://www.nlm.nih.gov/copyright.html Brigatinib https://www.ncbi.nlm.nih.gov/books/NBK500917/ EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking BRIGATINIB https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory Human Metabolome Database (HMDB) http://www.hmdb.ca/citing Brigatinib http://www.hmdb.ca/metabolites/HMDB0249380 NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse Alunbrig (Brigatinib) https://www.cancer.gov/about-cancer/treatment/drugs/brigatinib NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html https://rxnav.nlm.nih.gov/id/rxnorm/1921217 Protein Data Bank in Europe (PDBe) http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6GY PubChem https://pubchem.ncbi.nlm.nih.gov RCSB Protein Data Bank (RCSB PDB) https://www.rcsb.org/pages/policies https://www.rcsb.org/ Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=40061393-486257654 Thieme Chemistry. https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=40061393-486257654 Wikidata LICENSE CCZero https://creativecommons.org/publicdomain/zero/1.0/ brigatinib https://www.wikidata.org/wiki/Q27456393 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html brigatinib https://www.ncbi.nlm.nih.gov/mesh/2006884 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html KEGG LICENSE Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license https://www.kegg.jp/kegg/legal.html Therapeutic category of drugs in Japan http://www.genome.jp/kegg-bin/get_htext?br08301.keg USP drug classification http://www.genome.jp/kegg-bin/get_htext?br08302.keg Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Target-based classification of drugs http://www.genome.jp/kegg-bin/get_htext?br08310.keg Drug Groups http://www.genome.jp/kegg-bin/get_htext?br08330.keg Drug Classes http://www.genome.jp/kegg-bin/get_htext?br08332.keg UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html NORMAN Suspect List Exchange LICENSE Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0 https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ PATENTSCOPE (WIPO) SID 393116456 https://pubchem.ncbi.nlm.nih.gov/substance/393116456 Show More